Literature DB >> 25710878

Genetic variation of COLEC10 and COLEC11 and association with serum levels of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1).

Rafael Bayarri-Olmos1, Soren Hansen2, Maiken Lumby Henriksen2, Line Storm3, Steffen Thiel3, Peter Garred1, Lea Munthe-Fog1.   

Abstract

Collectin liver 1 (CL-L1, alias CL-10) and collectin kidney 1 (CL-K1, alias CL-11), encoded by the COLEC10 and COLEC11 genes, respectively, are highly homologous soluble pattern recognition molecules in the lectin pathway of complement. These proteins may be involved in anti-microbial activity and in tissue development as mutations in COLEC11 are one of the causes of the developmental defect syndrome 3MC. We studied variations in COLEC10 and COLEC11, the impact on serum concentration and to what extent CL-L1 and CL-K1 serum concentrations are correlated. We sequenced the promoter regions, exons and exon-intron boundaries of COLEC10 and COLEC11 in samples from Danish Caucasians and measured the corresponding serum levels of CL-L1 and CL-K1. The median concentration of CL-L1 and CL-K1 was 1.87 μg/ml (1.00-4.14 μg/ml) and 0.32 μg/ml (0.11-0.69 μg/ml), respectively. The level of CL-L1 strongly correlated with CL-K1 (ρ = 0.7405, P <0.0001). Both genes were highly conserved with the majority of variations in the non-coding regions. Three non-synonymous variations were tested: COLEC10 Glu78Asp (rs150828850, minor allele frequency (MAF): 0.003), COLEC10 Arg125Trp (rs149331285, MAF: 0.007) and COLEC11 His219Arg (rs7567833, MAF: 0.033). Carriers of COLEC10 Arg125Trp had increased CL-L1 serum levels (P = 0.0478), whereas promoter polymorphism COLEC11-9570C>T (rs3820897) was associated with decreased levels of CL-K1 (P = 0.044). In conclusion, COLEC10 and COLEC11 are highly conserved, which may reflect biological importance of CL-L1 and CL-K1. Moreover, the strong inter individual correlation between the two proteins suggests that a major proportion are found as heterooligomers or subjected to the same regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25710878      PMCID: PMC4339841          DOI: 10.1371/journal.pone.0114883

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Collectins are C-type lectins, a family of pattern recognition molecules involved in innate immunity. Collectins share a common multimeric structure where a basic subunit composed of three polypeptide chains undergoes varying degrees of oligomerization [1]. The polypeptide chains are composed of a collagen-like region, an alpha helical neck domain and a carbohydrate recognition domain (CRD). Through the clustering of the CRDs the collectins are capable of recognizing and binding to glycoconjugates on the surface of pathogens or to altered host cells, thereby facilitating their clearance [2]. Well-characterized collectins comprise mannose-binding lectin (MBL), surfactant protein A (SP-A) and D (SP-D), whose functions have been extensively studied [2]. MBL is a recognition molecule in the lectin pathway of complement along with Ficolin-1, Ficolin-2 and Ficolin-3. More recently described collectins comprises CL-L1 (alias collectin-10, collectin liver 1 or CL-10) [3], CL-K1 (alias collectin-11, collectin kidney 1 or CL-11) [4], and CL-P1 (alias collectin-12, collectin placenta 1, CL-12 or SRCL). Both CL-L1 and CL-K1 are soluble molecules that have been found circulating in blood in complex with lectin complement pathway associated serine proteases (MASPs) [5-8]. Two genes, MASP1 and MASP2, encode MASP-1/-3 (alias MASP1 isoform 1 and 2) and MASP-2 (alias MASP2 isoform 1), respectively, and encode also the alternatively spliced non-catalytic products, MAP-1 (alias MAp44 or MASP1 isoform 3) and sMAP (alias MAp19, MAP-2 or MASP2 isoform 2), respectively [9]. The COLEC10 gene encoding CL-L1 comprises six exons, is located on chromosome 8q23-q24.1 and is primarily expressed in the liver, placenta, and adrenal glands [3]. The protein-coding transcript gives rise to a 277 amino acid long protein with four defined regions: N-terminal segment (19 aa), collagen-like region (72 aa), alpha-helical coiled-coil neck region (34 aa), and the CRD (125 aa). The N-terminal segment and the first Gly-Xaa-Yaa repeat of the collagen-like region are encoded by exon 1 [10]; the rest of the collagen-like region by exons 2–4 (see also Fig. 1). Exon 5 encodes the neck region and exon 6 the CRD. Trimer assembly is stabilized by non-covalent interactions in the collagen-like and neck region, and inter-chain disulphide bonds between cysteine residues in the N-terminal segment (Cys12) and neck region (Cys119, Cys121) [7].
Fig 1

Distribution of polymorphisms and pair wise LD analysis (r2) observed in COLEC10.

A schematic drawing of the gene COLEC10 is given at the top. Exons are numbered and promoter and non-translated regions are indicated. The numbers in the grid refer to the r2 values of a given pair of SNPs. Darker colours of the boxes means higher r2 values.

Distribution of polymorphisms and pair wise LD analysis (r2) observed in COLEC10.

A schematic drawing of the gene COLEC10 is given at the top. Exons are numbered and promoter and non-translated regions are indicated. The numbers in the grid refer to the r2 values of a given pair of SNPs. Darker colours of the boxes means higher r2 values. The COLEC11 gene encoding CL-K1 comprises seven exons and is located on chromosome 2p25.3. The protein has a domain organization identical with CL-L1. CL-K1 has been found forming oligomers ranging from monomers to hexamers of the trimeric subunit, stabilized by inter chain disulfide bonds [5;8]. COLEC11 is predominantly expressed in the liver, fetal liver, adrenals gland, small intestine, thymus, spinal cord, placenta, pancreas and kidney but low expression levels are found in many other tissues [4]. The median circulating levels of CL-L1 and CL-K1 have been estimated to be 3 and 0.3 μg/ml respectively [5;11;7]. Recently, it was shown that CL-L1 and CL-K1 form heterooligomers, and that the heterooligomers comprise a major proportion of all circulating CL-L1 and CL-K1 [8]. This feature bears resemblance with C1q, the recognition molecule of the classical pathway of complement and with other C1q-related proteins [12]. The heteromeric trimers of C1q have a composition similar to CL-L1, CL-K1 heterooligomers, with heteromeric trimers consisting of polypeptide chains originating from different genes. Formation of the collectin heterooligomers leads, in comparison with CL-L1 and CL-K1 homooligomers alone, to a substantial higher degree of oligomerization and complement activation via interaction with MASP-2 [7;8]. Carbohydrate inhibition studies have shown that CL-K1 in addition to binding to mannose-like carbohydrates (e.g. L-fucose, alpha-D-methyl-mannose and D-mannose) also bind to bacterial and yeast extracts, as well as to apoptotic cells and intact microorganisms [4;5]. Moreover, murine CL-K1 was observed to reduce influenza virus A infectivity and to bind to DNA and heparin [5;8]. Native CL-L1 present in serum showed binding to L-fucose, D-mannose but these observations may be influenced by heteromeric complex formation with CL-K1 [7]. Recently it was shown that mutations in COLEC11 or in MASP1 are the common underlying causes of the Carnevale, Mingarelli, Malpuech and Michels syndromes, united in the syndrome now termed 3MC [13-17]. The clinical effect of variations in the serum concentration of CL-L1 and CL-K1 is more or less unknown. However, elevated CL-K1 plasma levels have been associated with the presence of disseminated intravascular coagulation (DIC), suggesting a possible pathophysiological role for CL-K1 in uncontrolled clotting and bleeding [18]. In the present report we have studied to what extent variations in the COLEC10 and COLEC11 may exist and how these variations affect the circulating levels of CL-L1 and CL-K1 in healthy individuals. To provide new insight into the presence of heterooligomeres in circulation we also aimed to evaluate the degree of correlation between serum levels of CL-L1 and CL-K1.

Materials and Methods

Donor samples

DNA was isolated from 296 unrelated Danish Caucasian blood donors using King Fisher (Thermo Scientific). Serum from 96 of the 296 blood donors was obtained for quantification of levels of CL-L1 and CL-K1. Samples were obtained with written informed consent, and the study was approved by the Regional Ethical Committee of the Capital Region of Denmark (H2–2011–133).

Sequencing of COLEC10 and COLEC11

COLEC10 and COLEC11 promoters and exonic regions were amplified using PCR (for sequences of the primers see Table 1). Promoters were sequenced as three partially overlapping fragments spanning 1000 bp upstream the translation start site ATG. All forward primers included a 5′-T7 sequence (5′-TAATACGACTCACTATAGGG-3′). PCR amplifications were carried out in 12 μl volumes containing 50 ng of genomic DNA, 0.25 μM of each primer, 2.5 mM MgCl2, 0.2 mM dNTP, 50 mM KCl, 10 mM Tris-HCl, pH 8.4, and 0.4 units of Platinum Taq DNA Polymerase (Invitrogen). The PCR reactions were performed according to the following setup: 120s94°C, 35x(10s94°C; 30s60°C; 45s72°C), 120s72°C. The PCR products were sequenced using a T7 biotinylated primer with the ABI BigDye cycle sequencing terminator kit (Applied Biosystems). Sequencing products were purified on the PyroMark Vacuum Prep Workstation (Biotage) using streptavidin beads (Genovision), and sequence analysis was performed on an ABI Prism 3100 Genetic Analyser (Applied Biosystems). The base-called sequences were aligned using BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and Chromas Lite (http://technelysium.com.au/) software. All chromatograms were confirmed visually.
Table 1

COLEC10 and COLEC11 primer sets.

Forward primerReverse primerInternal primer
COLEC10
 Promoter region
 Fragment 15′-cctttcacctaactcttagttga-3′5′-gcctttctggtacactatctc-3′
 Fragment 25′-ttcgcctttctgccacatcc-3′5′-gaactccagtgtgcatgtcag-3′
 Fragment 35′-tcaagtactcagcagaaggca-3′5′-caaagccattcattgctgtgg-3′
 Exonic regions
 Exon 15′-ggtccatttggagcactgag-3′5′-ataagtaacagaccagatctgg-3′
 Exon 25′-aagtgcatgtgaacatacatcc-3′5′-atgcaacttgagaaacatatgag-3′
 Exon 35′-tagtatatattcatactcactcac-3′5′-ccaccatgcccagctaattc-3′
 Exon 45′-ttatgactcatttaattagttgcac-3′5′-actgccagagttttctcttgg-3′
 Exon 55′-tttagaattgtcttatagttcattc-3′5′-cagacttgaggtgtcctagg-3′
 Exon 65′-tctgtgactacctcataatagg-3′5′-tgtaacctggcgagttattgg-3′
5′-gagtgccatcttaccatgtac-3′5′-aaggagaacttccaagtatagc-3′
 Pyrosequencing
 –7C>T5′-tgtgtgttccaaatacttccc-3′5′-[B]gactctgaatttgcaaaagaaatag-3′5′-tgggagacccttttctgagg-3′
 Glu78Asp5′-acattagccacatttcaaggga-3′5′-[B]acctcggtctctgagtgttg-3′5′-gtttgcttttcaggaattaaagg-3′
 Arg125Trp5′-[B]cgtgtcttcatcggcatca-3′5′-ctccttgtcaaactcacacatga-3′5′-ccacttgttgaaggtccgca-3′
COLEC11
 Promoter region
 Fragment 15′-tgtctggttttggtatcagggt-3′5′-gcttctatgcagcccgaatc-3′
 Fragment 25′-tcacctttgaacctagcttctta-3′5′-cctggggagtgtgggaac-3′
 Fragment 35′-ttgggatgttcgggttggag-3′5′-atcaaactttggaactctggtg-3′
 Exonic regions
 Exon 15′-ttgggatgttcgggttggag-3′5′-atcaaactttggaactctggtg-3′
 Exon 25′-ttggtgcctggtgctgacc-3′5′-ggaattccatggccgaagac-3′
 Exon 35′-aaacacaggccctttctaagag-3′5′-ccacaggtcagcacaaggag-3′
 Exon 45′-ctccattctatagtgtgtatgac-3′5′-agctgcagcccctccatcc-3′
 Exon 55′-aaagaatgatcactcgataatcc-3′5′-gtgtccaccgtgggatgtg-3′
 Exon 65′-ttgaaatacatgtgtctgccct-3′5′-gcacagccacaggcagcag-3′
 Exon 75′-acctcccagccctgtcctg-3′5′-cattttctcagtttagacaacagc-3′
5′-cccaacaatgcctacgacg-3′5′-catggataatagtgtgaaggaacc-3′
 Pyrosequencing
 His219Arg5′-[B]tggaaagagagcaaatgttcct-3′5′-actggaattgtagtgttgatgga-3′5′-actaatatccagttgtccaacaaa-3′

Forward and reverse primers were used for PCR amplification, internal primer was used for pyrosequencing. All forward primers for the promoter and exonic regions include a 5′-T7 sequence (5′-TAATACGACTCACTATAGGG-3′). Biotinylated oligos are indicated as [B].

Forward and reverse primers were used for PCR amplification, internal primer was used for pyrosequencing. All forward primers for the promoter and exonic regions include a 5′-T7 sequence (5′-TAATACGACTCACTATAGGG-3′). Biotinylated oligos are indicated as [B].

Pyrosequencing-based genotyping assay

Pyrosequencing was carried out as described by Munthe-Fog et al. [19]. In brief, specific primer sets were designed to amplify the three non synonymous SNPs found in COLEC10 and COLEC11, (rs150828850, rs149331285 and rs7567833) and the SNP located in the 5′UTR of COLEC10 (ss749616235) (for primer list see Table 1). DNA was PCR amplified and purified as described above. Purified PCR products were incubated 5 min at 85°C with 10 μM of internal primer and annealing buffer (magnesium acetate 2 mM, Tris 20 mM, pH 7.6). The pyrosequencing reaction and sequence analysis were carried out in the PSQ 96MA (Biotage).

SNP identification

The observed polymorphisms (Tables 2 and 3) can be found in NCBI’s SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/) through accession numbers (rs) or submission numbers (ss).
Table 2

Genetic variation observed in the COLEC10 gene.

VariationdbSNPRegionAmino acid changeAAAaaaMAF
−996C>Trs117863403Promoter-93 (96.9%)3 (3.1%)00.016
−796delTss991382312Promoter-95 (99%)1 (1%)00.005
−743C>Tss991382313Promoter-95 (99%)1 (1%)00.005
−742G>Ars3812490Promoter-94 (98%)2 (2%)00.010
−663C>Grs1485297Promoter-81(84.4%)14 (14.6%)1 (1%)0.083
−315G>Crs1485298Promoter-62 (64.6%)28 (29.2%)6 (6.3%)0.208
−277T>Crs2450048Promoter-56 (58.3%)33 (34.4%)7 (7.3%)0.245
−161_−157 delAAAATrs148350292Promoter-95 (99%)1 (1%)00.005
−150C>Trs3829048Promoter-93 (96.9%)3 (3.1%)00.016
−145G>Ass991382317Promoter-95 (99%)1 (1%)00.005
−7C>Tss7496162355′ UTR-299 (99.7%)1 (0.3%)00.005
+228A>Grs2465383Intron 1-26 (26%)55 (55%)19 (19%)0.465
+22418A>Grs16891987Exon 2-97 (97%)3 (3%)00.015
+22547T>Crs149290883Intron 2-99 (99%)1 (1%)00.005
+23881A>Crs150828850Exon 3Glu78Asp298 (99.3%)2 (0.7%)00.005
+23998A>Trs4512407Intron 3-97 (97%)3 (3%)00.015
+36545C>Trs149331285Exon 5Arg125Trp296 (98.7%)4 (1.3%)00.005
+38501C>Ars11987106Intron 5-97 (97%)3 (3%)00.015
+39097A>Grs10645563′ UTR-97 (97%)3 (3%)00.015
+39391C>Grs10645573′ downstream-97 (97%)3 (3%)00.015

The base position refers to the location of the polymorphism considering the A from the translation start site ATG as +1, and the adjacent 5′ base as -1. All variations adhered to the Hardy-Weinberg equilibrium. ‘AA’, individuals homozygote for the major allele; ‘Aa’, heterozygous individuals; ‘aa’, individuals homozygous for the minor allele; MAF, minor allele frequency.

Table 3

Genetic variation observed in the COLEC11 gene.

Base positiondbSNPRegionAmino acid changeAAAaaaMAF
−10007_− 10004delCATTss991382311Promoter-95 (99%)1 (1%)00.005
−9970T>Crs1864480Promoter-53 (55.2%)40 (41.7%)3 (3%)0.240
−9766T>Crs4849953Promoter-44 (45.8%)44 (45.8%)8 (8.4%)0.313
−9591G>Trs34596301Promoter-86 (89.6%)10 (10.4%)00.052
−9570C>Trs3820897Promoter-52 (54.2%)41 (42.7%)3 (3%)0.245
−9175T>Crs772467305′ UTR-193 (98.5%)3 (1.5%)00.010
+8822C>Trs3811531Intron 2-36 (36%)46 (46%)18 (18%)0.410
+8926G>Ars7567724Intron 2-77 (77%)20 (20%)3 (3%)0.130
+8939G>Ars17017752Intron 2-95 (95%)4 (4%)1 (1%)0.030
+9072G>Ars67826307Intron 3-95 (95%)4 (4%)1 (1%)0.030
+9091C>Trs72769325Intron 3-97 (97%)3 (3%)00.015
+33064T>Gss749616236Intron 3-99 (99%)1 (1%)00.005
+33116C>Trs3811528Intron 3-49 (49%)40 (40%)11 (11%)0.310
+33119G>Trs36024497Intron 3-99 (99%)1 (1%)00.005
+33125G>Ass749616237Intron 3-99 (99%)1 (1%)00.005
+33144A>Grs3811527Intron 3-49 (49%)40 (40%)11 (11%)0.310
+33145C>Trs148763047Intron 3-98 (98%)2 (2%)00.010
+33233T>Crs34347318Exon 4-98 (98%)2 (2%)00.010
+33245T>Crs17017791Exon 4-99 (99%)1 (1%)00005
+35844C>Trs17017804Intron 4-99 (99%)1 (1%)00.005
+35846C>Trs144784212Intron 4-99 (99%)1 (1%)00.005
+39141C>Trs34436491Exon 6-99 (99%)1 (1%)00.005
+39618C>Grs7567833Exon 7His219Arg280 (93.3%)20 (6.7%)00.025
+39739C>Trs114716171Exon 7-96 (96%)4 (4%)00.020

The base position refers to the location of the polymorphism considering the A from the translation start site ATG as +1, and the adjacent 5′ base as -1. All variations adhered to the Hardy-Weinberg equilibrium. ‘AA’; individuals homozygote for the major allele, ‘Aa’; heterozygous individuals, ‘aa’; individuals homozygous for the minor allele; MAF, minor allele frequency.

The base position refers to the location of the polymorphism considering the A from the translation start site ATG as +1, and the adjacent 5′ base as -1. All variations adhered to the Hardy-Weinberg equilibrium. ‘AA’, individuals homozygote for the major allele; ‘Aa’, heterozygous individuals; ‘aa’, individuals homozygous for the minor allele; MAF, minor allele frequency. The base position refers to the location of the polymorphism considering the A from the translation start site ATG as +1, and the adjacent 5′ base as -1. All variations adhered to the Hardy-Weinberg equilibrium. ‘AA’; individuals homozygote for the major allele, ‘Aa’; heterozygous individuals, ‘aa’; individuals homozygous for the minor allele; MAF, minor allele frequency.

In silico prediction of the biological consequences of variations

In silico analysis of functional effects was performed on the observed nsSNPs. PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) evaluates physical properties, proximity to functional structures, and the evolutive conservation to predict the functional significance of a mutation using a trained Naïve Bayes classifier [20]. BLOSUM62 (http://www.ncbi.nlm.nih.gov) is an amino acid substitution matrix that assigns a score to each aligned pair of residues based on the odds of finding both amino acids in an alignment on purpose rather than by chance. SIFT (http://sift.bii.a-star.edu.sg/) is a multi-step sequence alignment comparison algorithm that estimates whether an amino acid substitution may have an effect on protein function, based upon the premise that highly conserved residues are more intolerant to substitution than those less conserved [21;22]. Align-GVGD (http://agvgd.iarc.fr/) classifies a substitution from most likely to least likely to interfere with protein function based on multiple sequence alignments (MSA) and the combined Grantham Variation (GV) and Grantham Deviation (GV) scores, which measure the biochemical distance between aminoacids [23]. Protein MSA was constructed using ClustalW included in the program Bioedit (www.mbio.ncsu.edu/BioEdit/bioedit.html). CL-L1 and CL-K1 protein sequences were aligned with their orthologues from 17 different species in order to build a dataset with a sufficient size and alignment depth to compensate for the appearance of constrained positions due to chance [24;25]. PhD-SNP is a trained support vector machine-based predictor that classifies mutations as neutral polymorphisms or disease related based on sequence and profile information [26]. Furthermore, an evolutionary conservation profile was generated by Consurf [27]. This web-based program calculates the degree of conservation (from most variable to most conserved) for every position of the protein using MSA and an empirical Bayesian algorithm.

CL-L1 and CL-K1 levels in serum

The serum levels of CL-L1 and CL-K1 was quantified using validated double sandwich immuno assays as previously described in detail [7] and [28].

Statistical analysis

Hardy-Weinberg was calculated applying the χ2 test to the simple gene counting results, implementing Yates’ correction when considered appropriate. Linkage disequilibrium (LD), expressed as r2, and observed haplotypes were assessed by SHEsis software [29;30]. The statistical significance of the genetic impact on serum levels was tested with Mann-Whitney U test, Kruskal-Wallis test and Spearman Rank correlation. Whiskers and outliers were calculated according to Tukey’s method.

Results

Genetic variation in COLEC10 and COLEC11

We sequenced the promoter region spanning 1000 bp upstream the translation start site, the exon and intron/exon boundaries in COLEC10 and COLEC11. . A total of 10 known and novel variations were observed in the promoter region (Table 2) including a novel variation located in the 5’UTR. Another 10 variations were observed in the exons and the flanking regions. Two low frequent variations (MAF < 0.01) resulted in an amino acid change: Glu78Asp (rs150828850) and Arg125Trp (rs149331285). The Glu78Asp variation in exon 3 occurs in a variable residue and was predicted to be benign, in contrast to Arg125Trp in exon 6, which is located in an evolutionary constrained position in the neck domain and was by in silico analysis predicted to be potentially critical for the structure (Table 4). A complete list of observed variations and linkages are given in Table 2 and Fig. 1. To test whether any of the identified variations were located within a regulatory domain, all promoter variations were analyzed in silico (SwissRegulon Database). COLEC10 161_-157AAAATdel overlaps with a SRY and several Forkhead box (FOX) binding sites. SRY and the FOX family of transcription factors are known regulators of multiple cellular and developmental processes such as liver differentiation [31;32]. Of interest, additional perfect LD was observed between seven loci; COLEC10–7 (ss749616235), +22418 (rs16891987), +22547 (rs149290883), +23998 (rs4512407), +38501 (rs11987106), +39097 (rs1064556), and +39391 (rs1064557), however, these minor alleles were clustered in 4 individuals only.
Table 4

Non-synonymous variations in COLEC10 and COLEC11.

VariationRegionPolyPhen-2Blosum62SIFTAlign-GVGDPhD-SNPConsurf
COLEC10 Glu78Asp (rs150828850)Exon 3Benign21C0Neutral (7)Variable(3)
COLEC10 Arg125Trp (rs149331285)Exon 5Probably damaging-30C65Disease (3)Conserved (9)
COLEC11 His219Arg (rs7567833)Exon 7Benign00.46229Neutral (3)Variable(3)

PolyPhen-2 classifies qualitatively a mutation as benign, possibly damaging, or probably damaging. BLOSUM62 matrix values range from 4 (more likely) to -4 (less likely substitutions). SIFT values >0.05 indicate substitutions with little effect on protein function, while values <0.05 point out possible deleterious substitutions. Align-GVGD categorizes a mutation in seven graded classifiers from less likely (class C0) to most likely to interfere with protein function (class C65). PhD-SNP produces a binary prediction (neutral vs disease-related polymorphism), together with the reliability score of the prediction (0–9). Consurf position-specific conservation scores are divided in 9 grades, from the most variable (grade 1) to the most conserved positions (grade 9).

PolyPhen-2 classifies qualitatively a mutation as benign, possibly damaging, or probably damaging. BLOSUM62 matrix values range from 4 (more likely) to -4 (less likely substitutions). SIFT values >0.05 indicate substitutions with little effect on protein function, while values <0.05 point out possible deleterious substitutions. Align-GVGD categorizes a mutation in seven graded classifiers from less likely (class C0) to most likely to interfere with protein function (class C65). PhD-SNP produces a binary prediction (neutral vs disease-related polymorphism), together with the reliability score of the prediction (0–9). Consurf position-specific conservation scores are divided in 9 grades, from the most variable (grade 1) to the most conserved positions (grade 9). . Four known variations and a novel 4-bp deletion were observed in the promoter region (Fig. 2, Table 3). In the 5’UTR and the intron/exon boundaries 12 known and two novel variations were identified. Further five variations were found within the exons, one resulting in an amino acid change: His219Arg (rs7567833) located in exon 7, which encodes the carbohydrate recognition domain of CL-K1. Only individuals heterozygous for His219Arg were identified (N = 5, MAF 0.025). His219Arg showed a moderate linkage with +33245 in exon 4 (rs17017791), +35844 in intron 4 (rs17017804), +39141 in exon 4 (rs34436491); and more robust linkage with +9091 in intron 3 (rs72769325). In addition, two SNPs in intron 3, rs3811528 and rs3811527 (+8939 and +9072), with MAFs of 0.31 had a perfect LD.
Fig 2

Distribution of polymorphisms and pair wise LD analysis (r2) observed in COLEC11.

A schematic drawing of the gene COLEC11 is given at the top. Exons are numbered and promoter and non-translated regions are indicated. The numbers in the grid refer to the r2 values of a given pair of SNPs. Darker colours of the boxes means higher r2 values.

Distribution of polymorphisms and pair wise LD analysis (r2) observed in COLEC11.

A schematic drawing of the gene COLEC11 is given at the top. Exons are numbered and promoter and non-translated regions are indicated. The numbers in the grid refer to the r2 values of a given pair of SNPs. Darker colours of the boxes means higher r2 values.

Serum levels

CL-L1 mean serum concentration was estimated to be 1.87 μg/ml (range 1.00—l4.14 μg/ml). CL-K1 serum concentration ranged from 0.11 to 0.69 μg/ml, with a mean concentration of 0.32 μg/ml. None of the highly frequent polymorphisms in the COLEC10 promoter region were associated with CL-L1 serum levels. Interestingly, although no individuals homozygous for the minor allele were found, individuals heterozygous for Arg125Trp (rs149331285) (N = 3) had significantly higher levels of CL-L1 in serum (P = 0.0478, Fig. 3A).
Fig 3

Impact of allelic variants on serum levels.

A-C, the serum levels of CL-L1 and CL-K1 and the corresponding genotype. Horizontal bars indicate median values; number in parenthesis, number of individuals and white circles, outliers. Statistical significance was determined by non-parametric Mann-Whitney and Kruskal-Wallis tests. D, the distribution of CL-L1 and CL-K1 levels in the cohort. The strength of the correlation was calculated using Spearman Rank.

Impact of allelic variants on serum levels.

A-C, the serum levels of CL-L1 and CL-K1 and the corresponding genotype. Horizontal bars indicate median values; number in parenthesis, number of individuals and white circles, outliers. Statistical significance was determined by non-parametric Mann-Whitney and Kruskal-Wallis tests. D, the distribution of CL-L1 and CL-K1 levels in the cohort. The strength of the correlation was calculated using Spearman Rank. In COLEC11 the promoter polymorphism—9570C>T (rs3820897) was significantly associated with higher levels of CL-K1 (P = 0.044, Fig. 3B). The non-synonymous SNP; His219Arg had no significant effect on the level of CL-K1 (Fig. 3C). The allele count for several of the genotyped positions was too low to significantly determine the impact on the level of circulating proteins. A strong correlation, independent of age and gender (not shown) between CL-L1 and CL-K1 (ρ = 0.7405, P <0.0001) was observed (Fig. 3D). However, none of the identified genetic variations in COLEC10 were significantly associated with the circulating levels of CL-K1 and vice versa (data not shown), thus COLEC10 Arg125Trp was not associated with the level of CL-K1 (P = 0.916) and neither was COLEC11–9570C>T with the level of CL-L1 (P = 0.938).

Discussion

To study how the genetic variation affects structure and concentrations in the background population we examined the COLEC10 and COLEC11 in healthy individuals and determined the circulating levels of CL-L1 and CL-K1 in corresponding serum samples. Screening COLEC10 and COLEC11, we found two variations with a putative impact on either serum level and/or protein structure. COLEC10 Arg125Trp (rs149331285) was predicted by in silico analysis to have a significant effect on protein structure. This nsSNP is located in the neck domain, an alpha helical coiled-coil region involved in the trimerization of the collagen chains. The helical coil region consists of three parallel right-handed alpha helices with hydrophobic residues repeated in a heptad pattern. The association of the alpha helices aligns the collagen chains allowing them to fold in a zipper-like fashion. There is extensive evidence that oligomerization of SP-D monomers is required for high-affinity binding to carbohydrates [33] and for many of its biological functions [34;35]. Thus, COLEC10 Arg125Trp may be of considerable importance if the substitution disrupts the coil structure causing the trimers to fall apart or affect the assembly of heteromeric complexes. Curiously, the level of CL-L1 was significantly higher in the three heterozygous individuals we identified. With a calculated MAF of 0.005, this variation would be interesting to characterize further. Although only present in three individuals the promoter polymorphism COLEC11–9570C>T (rs3820897) was significantly associated with the level of CL-K1 (P = 0.044). We identified several other variations that potentially could influence the protein levels in serum. However, due to limitations in our cohort size the impact of the genetic variation on the circulating levels require further analyses in larger cohorts. Among the more interesting variations is the COLEC10–161–157AAAATdel expected to interrupt the binding site of several transcription factors that regulate an array of events ranging from liver development (e.g. FOXA2) [31] to immune response modulation (FOXJ1, FOXO3, FOXQ1) [36]. Additional studies into COLEC10 and COLEC11 regulatory cassettes could resolve these questions. No effect on serum levels was observed for the polymorphism COLEC11 His219Arg (rs7567833, MAP 0.033), located in the carbohydrate recognition domain. Phylogenetic analysis revealed that the G allele (the minor allele) is indeed the ancestral allele. Although located adjacent to the ligand binding site in the CRD, this substitution could affect the binding affinity of the variant molecule towards its ligand as seen for Ficolin-2 [37]. Amino acid substitutions in the pathogen recognition domain affecting the ligand binding have previously been reported for Ficolin-2. Two non-synonymous polymorphisms in FCN2 positioned near the binding site markedly alter the binding capacity for GlcNAc and thus the complement activation potential [37]. Several Ficolin-2 clinical associations have been reported and genotypes conferring low lectin activity have been associated with increased risk of infections [38]. Thus, COLEC11 His219Arg could be of clinical relevance. Recently, heteromeric complexes between CL-L1 and CL-K1, stabilized by disulfide bonds, were observed in circulation by Henriksen et al [8]. The observation was further supported by co-transfections of the two proteins in CHO cells in which the ratio of CL-L1 and CL-K1 in the formed heteromeric complexes was estimated to 1:2 in favor of CL-K1. Both recombinant CL-K1 and CL-L1 and the heterocomplexes from serum are able to form complexes with the MASPs leading to activation of the complement cascade. In addition, the complement activation potential of the heterocomplexes was reported to be more potent than the potential observed for CL-K1 homocomplexes [8]. In the present study we observed a strong correlation between CL-L1 and CL-K1 serum levels (ρ = 0.7405, Fig. 3C), independent of age or gender lending support to the above observation that a major proportion of CL-L1 and CL-K1 exist as heterooligomeric complexes in the circulation whereas only a minor part of CL-L1 and CL-K1 circulates as homocomplexes. A more definite prediction of the composition of the heterocomplexes i.e. the CL-L1:CL-K1 ratio would be highly speculative as the relatively large difference in levels between CL-L1 and CL-K1 could be due to differences in the techniques for estimating the protein concentration. In conclusion, we report the finding of three gene variations in COLEC10 and COLEC11 with putative effect on the circulating levels and function of CL-L1 and CL-K1. COLEC10 Arg125Trp (rs149331285) was predicted to have a significant effect on the protein structure however carriers of the variant had significant higher levels of circulating CL-L1. In COLEC11 the promoter polymorphism COLEC11–9570C>T (rs3820897) was significantly associated with the level of CL-K1. Furthermore, located in the CRD of CL-K1 the polymorphism COLEC11 His219Arg (rs7567833) could potentially affect the binding capacity of CL-K1 towards its ligand thereby altering the lectin pathway activation potential of CL-K1. Thus, our study offers an overview of COLEC10 and COLEC11 sequence-variant footprint in the Caucasian population and the observations made here will serve to establish more detailed footprint for genotype-phenotype studies in the Caucasian population as well as in other ethnic groups.
  38 in total

1.  Molecular cloning of a novel human collectin from liver (CL-L1).

Authors:  K Ohtani; Y Suzuki; S Eda; T Kawai; T Kase; H Yamazaki; T Shimada; H Keshi; Y Sakai; A Fukuoh; T Sakamoto; N Wakamiya
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

2.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci.

Authors:  Yong Yong Shi; Lin He
Journal:  Cell Res       Date:  2005-02       Impact factor: 25.617

Review 3.  Forkhead transcription factors in immunology.

Authors:  H Jonsson; S L Peng
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

4.  Two sisters with a syndrome of ocular, skeletal, and abdominal abnormalities (OSA syndrome).

Authors:  R Mingarelli; A Castriota Scanderbeg; B Dallapiccola
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

5.  Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information.

Authors:  E Capriotti; R Calabrese; R Casadio
Journal:  Bioinformatics       Date:  2006-08-07       Impact factor: 6.937

6.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

7.  Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2.

Authors:  Tina Hummelshoj; Lea Munthe-Fog; Hans O Madsen; Teizo Fujita; Misao Matsushita; Peter Garred
Journal:  Hum Mol Genet       Date:  2005-05-06       Impact factor: 6.150

8.  Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D. Expression of a trimeric protein with altered anti-viral properties.

Authors:  P Brown-Augsburger; K Hartshorn; D Chang; K Rust; C Fliszar; H G Welgus; E C Crouch
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

9.  Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies.

Authors:  K L Hartshorn; K B Reid; M R White; J C Jensenius; S M Morris; A I Tauber; E Crouch
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

10.  ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures.

Authors:  Meytal Landau; Itay Mayrose; Yossi Rosenberg; Fabian Glaser; Eric Martz; Tal Pupko; Nir Ben-Tal
Journal:  Nucleic Acids Res       Date:  2005-07-01       Impact factor: 16.971

View more
  13 in total

1.  Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus.

Authors:  A Troldborg; S Thiel; L Jensen; S Hansen; M J Laska; B Deleuran; J C Jensenius; K Stengaard-Pedersen
Journal:  Clin Exp Immunol       Date:  2015-08-31       Impact factor: 4.330

2.  The pattern recognition molecule collectin-L1 in critically ill children.

Authors:  Catherine Ingels; Ilse Vanhorebeek; Inge Derese; Lisbeth Jensen; Pieter J Wouters; Steffen Thiel; Greet Van den Berghe
Journal:  Pediatr Res       Date:  2016-04-08       Impact factor: 3.756

3.  Protective Role of Collectin 11 in a Mouse Model of Rheumatoid Arthritis.

Authors:  Na Wang; Weiju Wu; Cui Qiang; Ning Ma; Kunyi Wu; Dan Liu; Jia-Xing Wang; Xiao Yang; Li Xue; Teng-Yue Diao; Jia-Yu Liu; Ang Li; Baojun Zhang; Zong-Fang Li; Conrad A Farrar; Nirmal K Banda; Rafael Bayarri-Olmos; Peter Garred; Wuding Zhou; Ke Li
Journal:  Arthritis Rheumatol       Date:  2021-07-07       Impact factor: 15.483

4.  Particulate matter, the newborn methylome, and cardio-respiratory health outcomes in childhood.

Authors:  Carrie V Breton; Lu Gao; Jin Yao; Kimberly D Siegmund; Fred Lurmann; Frank Gilliland
Journal:  Environ Epigenet       Date:  2016-06-12

5.  Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1).

Authors:  Rafael Bayarri-Olmos; Nikolaj Kirketerp-Moller; Laura Pérez-Alós; Karsten Skjodt; Mikkel-Ole Skjoedt; Peter Garred
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

6.  Decreased expression of COLEC10 predicts poor overall survival in patients with hepatocellular carcinoma.

Authors:  Baozhu Zhang; Haibo Wu
Journal:  Cancer Manag Res       Date:  2018-08-01       Impact factor: 3.989

7.  Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease.

Authors:  Thaisa Lucas Sandri; Fabiana Antunes Andrade; Kárita Cláudia Freitas Lidani; Elias Einig; Angelica Beate Winter Boldt; Benjamin Mordmüller; Meral Esen; Iara J Messias-Reason
Journal:  PLoS Negl Trop Dis       Date:  2019-04-17

8.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  COLEC10 is mutated in 3MC patients and regulates early craniofacial development.

Authors:  Mustafa M Munye; Anna Diaz-Font; Louise Ocaka; Maiken L Henriksen; Melissa Lees; Angela Brady; Dagan Jenkins; Jenny Morton; Soren W Hansen; Chiara Bacchelli; Philip L Beales; Victor Hernandez-Hernandez
Journal:  PLoS Genet       Date:  2017-03-16       Impact factor: 5.917

10.  CL-L1 and CL-K1 Exhibit Widespread Tissue Distribution With High and Co-Localized Expression in Secretory Epithelia and Mucosa.

Authors:  Soren W K Hansen; Josephine B Aagaard; Karen B Bjerrum; Eva K Hejbøl; Ole Nielsen; Henrik D Schrøder; Karsten Skjoedt; Anna L Sørensen; Jonas H Graversen; Maiken L Henriksen
Journal:  Front Immunol       Date:  2018-07-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.